Summary & Overview
HCPCS G9139: CML Disease Status, Philadelphia Chromosome Positive, Staging in Progress
HCPCS Level II code G9139 identifies an oncology disease-status entry for chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive and/or BCR-ABL positive when the extent of disease is unknown and staging is ongoing. The code is designated for use in a Medicare-approved demonstration project and functions primarily as a reporting or tracking code during diagnostic or staging workflows. Nationally, accurate use of this code supports standardized reporting of CML disease status and can inform programmatic evaluations within demonstration projects.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise guidance on the clinical context of G9139, its service setting implications, and what to expect when this code appears on claims or encounter records. The publication outlines benchmarks and policy considerations relevant to demonstration-project reporting, clarifies the service type and typical site of service, and summarizes how G9139 fits into oncology staging workflows. Data not available in the input is explicitly noted where applicable, and the discussion remains national in scope without state-specific references.
Billing Code Overview
HCPCS Level II code G9139 denotes an oncology status designation specific to chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive and/or BCR-ABL positive where the extent of disease is unknown and staging is in progress. The description indicates this code is for use within a Medicare-approved demonstration project, reflecting a reporting or tracking purpose rather than a definitive staging result.
-
Service type: Oncology disease status assessment and staging in progress
-
Typical site of service: Oncology clinic or hospital outpatient setting where diagnostic staging and disease-status reporting for CML occur
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with newly suspected chronic myelogenous leukemia (CML) is referred to a tertiary oncology center participating in a Medicare-approved demonstration project. The patient presents with fatigue, splenomegaly on exam, elevated white blood cell count, and preliminary laboratory testing that suggests a myeloproliferative disorder. Cytogenetic testing and molecular assays are ordered to confirm Philadelphia chromosome positivity or BCR-ABL fusion. Staging and disease status assessment are in progress; results are pending, and the exact extent of disease is not yet determined. Care coordination includes hematology-oncology consultation, bone marrow aspiration/biopsy, peripheral blood cytogenetics, polymerase chain reaction (PCR) for BCR-ABL transcript quantification, and initiation planning for tyrosine kinase inhibitor therapy if confirmed. Documentation supports use of G9139 for reporting disease status of chronic myelogenous leukemia limited to Philadelphia chromosome positive and/or BCR-ABL positive when used within the scope of the Medicare demonstration project, while staging and definitive extent remain under evaluation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typical for the service due to complexity of disease-status documentation or prolonged coordination within the demonstration project. |